Can a simple blood test predict immunotherapy results for melanoma patients?

NCT ID NCT03348891

Completed Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs. Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for biological markers that might predict whether the treatment would work. The goal was to find clues that could help doctors choose the best therapy for each patient in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which melanoma patients will benefit from specific immunotherapy combinations.
What could go wrong: This is an observational study, not a treatment trial. It may not find clear markers, and results may not change patient care directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

CHRU Claude HURIEZ

Lille, France
CHU Montpellier Saint-Eloi

Montpellier, France
Institut Universitaire du Cancer de Toulouse - Oncopole

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.